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Iron overload in kidney transplants: Prospective analysis of
biochemical and genetic markers.
Background. The prevalence of iron overload and the influ-
ence of mutations in the HFE and TRF2 gene on biochemical
markers of iron overload among renal transplant patients is un-
known.
Methods. Serum iron, ferritin, transferrin saturation (TSAT),
and liver function parameters were analyzed in a cohort of 438
renal transplants. In patients with iron overload, the time course
of biochemical markers of iron status as well as the influence of
iron loading mutations was investigated during a time period of
5 years.
Results. Of 438 renal transplant patients 41 (9.4%) presented
with an iron loading phenotype (TSAT above 40% and/or
ferritin above 800 ng/mL). Mutations in the HFE gene were
present in 12 of 33 (36.3%) patients with iron overload. Among
these one patient was homozygous for HFE C282Y, and two
patients were compound heterozygous for HFE C282Y/H63D.
No individual tested positive for nine other mutations in HFE
as well as theTRF2 Y250X mutation. Over time we observed a
decrease of mean iron and ferritin levels, and of mean TSAT
in our study sample. In patients with mutations in HFE this
decrease was less pronounced as compared to patients with-
out mutations. We found an independent positive association
between the presence of mutations in HFE and serum alanine-
aminotransferase levels at follow-up (P = 0.003).
Conclusion. Our study demonstrates that iron overload is
frequently present in renal transplant patients and shows a con-
tinuous decrease over time. This decrease is possibly impaired
by the HFE C282Y and HFE H63D mutations. Furthermore,
mutations in HFE may influence liver function as reflected by
increased alanine-aminotransferase concentrations.
Iron overload refers to all conditions where excessive
amounts of iron accumulate in the body ultimately result-
ing in parenchymal damage and organ dysfunction. Iron
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overload diseases can be due to inherited traits (primary
iron overload) and/or acquired conditions (secondary
iron overload) [1].
In recent years important insights into primary iron
overload have emerged from studies of adult hereditary
hemochromatosis. This is a genetically heterogeneous
disease that is caused by mutations in at least two genes
(HFE and TRF2) of iron metabolism [2, 3] and shows a
late onset of iron deposition predominantly in the liver
[4]. In patients with hereditary hemochromatosis contin-
ued absorption of iron occurs despite increasing body
iron. Before significant amounts of iron are deposited
in tissues, superfluous iron is released to the plasma fol-
lowed by an increase of the transferrin saturation which
is an early sign of developing iron overload [1]. As the
years pass accumulating iron is stored in various tissues
raising plasma ferritin levels. Thus, under normal circum-
stances transferrin saturation (TSAT) and the amount of
circulating ferritin is related to the quantity of body iron
stores [5]. However, serum ferritin and TSAT can be ele-
vated out of proportion to iron stores limiting their value
in diagnosing iron overload.
Important nongenetic factors contributing to iron over-
load (secondary iron overload) include iron supple-
mentation and blood transfusions. Patients with renal
insufficiency under different forms of renal replacement
therapy are at risk for development of secondary iron
overload for several reasons: First, before introduction
of erythropoietin therapy for correction of renal ane-
mia they frequently received blood transfusions on a
regular basis. Second, since introduction of treatment
with erythropoiesis-stimulating agents these patients rou-
tinely receive iron supplementation for successful treat-
ment of renal anemia. Therefore, patients with renal
insufficiency under different forms of renal replacement
therapy represent a model to study the influence of
genetic factors in an environment of secondary iron
overload.
In the present study, we investigated biochemical
markers of iron status and liver function over a time
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period of 5 years among stable renal transplant patients
with an iron loading phenotype as defined by serum fer-
ritin levels of more than 800 ng/mL and/or a TSAT above
40%. We also considered mutations in the HFE and TRF2
genes.
METHODS
Study design and patients
The aim of the study was to investigate the influence
of the HFE and TRF2 genotype on biochemical mark-
ers of iron status and liver function over a time period
of 5 years in a study population with biochemical signs
of iron overload. Therefore a nested cohort study was
designed. Patients were recruited from 438 stable kidney
graft recipients. The detailed patient characteristics have
been described previously [6]. Inclusion criteria were a
phenotype of iron overload with a TSAT in serum above
40% according to the American Hemochromatosis So-
ciety (http://www.americanhs.org) and/or a serum ferritin
concentration of more than 800 ng/mL.
Biochemical methods
Blood chemistry was analyzed by standard meth-
ods. Serum iron, aspartate-aminotransferase (ASAT),
alanine-aminotransferase (ALAT), gamma-glutamyl-
transferase (GGT), cholinesterase, C-reactive protein
(CRP), and creatinine levels were measured using a
Hitachi 747 analyzer (Roche Diagnostics, Mannheim,
Germany). Serum transferrin concentrations were deter-
mined by the Behring Nephelometer II analyzer (Dade
Behring, Liederbach, Germany). Serum ferritin levels
were analyzed with a Hitachi 911 instrument (Roche Di-
agnostics). The prothrombin time (PT) was determined
using the STA coagulation analyzer (Roche Diagnos-
tics). The TSAT was calculated by the formula serum
iron (g/dL)/serum transferrin (mg/dL) × 70.9, respec-
tively. The creatinine clearance was calculated using the
equation of Cockcroft and Gault [7]. Hemoglobin lev-
els and percentages of hypochromic red blood cells were
analyzed with the Technicon H∗2 hematology analyzer
(Bayer Diagnostics, Tarrytown, NY, USA).
Genotyping
Mutation analyses were performed by reverse hy-
bridization using the Haemochromatosis StripAssay A
test system (ViennaLab, Vienna, Austria). This assay
allows for simultaneous investigation of eleven muta-
tions in the HFE gene, including V53M, V59M, H63D,
H63H, S65C, Q127H, E168Q, E168X, W169X, C282Y,
and Q283P as well as the TRF2 X250Y mutation [8].
Statistical analysis
Continuous data are given as means ± standard devia-
tion or as median and ranges. Categorical data are given
as absolute counts and percentages.
We analyzed univariate associations of iron levels, of
ferritin levels and of TSAT (at baseline and at follow-
up) with age, gender, time since transplantation, time
since initiation of renal replacement therapy, serum cre-
atinine, estimated creatinine clearance, ASAT, ALAT,
GGT, cholinesterase, PT, CRP, hemoglobin, and pro-
portion of hypochromic red blood cells by Pearson’s
correlation.
We compared paired and unpaired data by Student t
test.
Forward stepwise multiple linear regression models
were established to examine independent predictors of
TSAT, ALAT, ASAT, and GGT at follow-up. We in-
cluded all variables in this model that showed a univariate
association with iron level, ferritin level, or TSAT.
All analyses were performed using Statistica for
Windows 5.1 (Stat Soft, Inc., 1997, Tulsa, OK, USA).
RESULTS
Patients
Of 438 renal transplant patients 41 (9.4%) fulfilled
the criteria of iron overload. Eleven patients showed a
TSAT >40% and a ferritin level >800 ng/mL, 16 patients
showed a TSAT >40% but a ferritin level <800 ng/mL,
and 14 patients had a ferritin level >800 ng/mL but a
TSAT <40%. The baseline characteristics of all patients
are shown in Table 1. During the follow up time of 5 years,
eight patients died and one patient was lost for follow up.
For one patient TSAT was not available at follow up.
At this time point 15 patients showed biochemical signs
of iron overload. Four patients showed a TSAT >40%
and a ferritin level >800 ng/mL, seven patients showed a
TSAT >40%, and four patients presented with a ferritin
level >800 ng/mL.
HFE and TRF2 mutations
DNA for mutation analysis was available from 33 of
the 41 patients. Mutations in the HFE gene were present
in 12 of 33 (36.3%) patients with iron overload. One pa-
tient was homozygous for HFE C282Y, two patients were
compound heterozygous for HFE C282Y/H63D, two in-
dividuals were heterozygous for C282Y, and seven pa-
tients were heterozygous for H63D. None of the patients
showed other mutations in the HFE gene. Furthermore,
no individual tested positive forTRF2 Y250X.
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Table 1. Patient characteristics [median (range) or count (frequency)]
All patients (N = 438) Iron loading phenotype (N = 41) Genetically tested (N = 33)
Men/women % 261 (59.6)/177 (40.4) 19 (46)/22 (54) 19 (58)/14 (42)
Age years 53.6 (16.1; 79.9) 54.4 (24.9; 72.7) 54.4 (24.9; 72.3)
Transplanted since years 4.4 (0.1; 29.4) 2.9 (1; 29.4) 3.3 (0.1; 9.3)
Serum creatinine mg/dL 1.6 (0.7; 6.1) 1.6 (1.0; 3.0) 1.5 (1.0; 2.9)
Creatinine clearance mL/min 52.7 (12.8; 110.6) 51.7 (18.1; 97.8) 55.5 (18.1; 97.8)
Hemoglobin g/dL 13.0 (7.6; 19.5) 12.6 (10.0; 16.9) 12.4 (10.0; 16.9)
% Hypochromic red blood cells 0.9 (0; 66.4) 0.7 (0.1; 9.6) 0.6 (0.1; 9.6)
Transferrin saturation % 21.3 (1.75; 84.0) 42.7 (10.5; 84.0) 42.8 (10.5; 84.0)
Serum ferritin ng/mL 82.4 (0.5; 3300) 977 (20.6; 3300) 933 (20.6; 3300)
C-reactive protein above normal % 34 (0.08) 2 (5) 1 (3)
Patients on current EPO therapy % 29 (6.6) 2 (5) 2 (6)
EPO is erythropoietin.
Time course of iron parameters according to
HFE mutations
The time course of the biochemical markers of iron
overload as well as the association of the HFE geno-
type with these markers was investigated in 33 patients.
Among 21 patients without mutation, five individuals
showed a TSAT >40% and a ferritin level >800 ng/mL,
nine patients showed a TSAT >40%, and seven patients
presented with a ferritin level >800 ng/mL at baseline. At
follow-up two patients showed a TSAT >40% and a fer-
ritin level >800 ng/mL, seven patients showed a TSAT
>40%, and one patient presented with a ferritin level
>800 ng/mL.
Among 12 patients with mutations in HFE, four in-
dividuals showed a TSAT >40% and a ferritin level
>800 ng/mL, four patients showed a TSAT >40%, and
four patients presented with a ferritin level >800 ng/mL
at baseline. At follow-up two patients showed a TSAT
>40% and a ferritin level >800 ng/mL, two patients
showed a TSAT >40%, and one patient presented with
a ferritin level >800 ng/mL.
The time course of indicators of iron overload for pa-
tients with and without mutations in HFE is shown in
Table 2. We observed a decrease of mean iron levels,
of mean ferritin levels, and of mean TSAT in our study
sample. In patients with mutations in HFE this decrease
was somewhat less pronounced as compared to patients
without mutation in HFE (Table 2). Comparison of the
difference of iron levels, of ferritin levels, and of TSAT
between baseline and follow-up revealed a trend for a
less pronounced decrease of iron parameters in patients
with mutations in the HFE gene (Table 3).
The time course of the markers of iron status according
to the different HFE mutations is shown in Table 4.
Independent predictors of the TSAT at follow-up are
indicated in Table 5. GGT, ALAT, time since transplan-
tation in years, creatinine clearance, and age were pre-
dictors of an iron loading phenotype after a follow-up
time of 5 years. Hepatitis C infection was negatively
associated with TSAT among iron overloaded patients
(Table 5).
Time course of liver enzymes according to
HFE mutations
The course of the liver enzymes in patients with and
without mutations in HFE is indicated in Table 6. We
observed no significant variation of liver enzymes during
the observation period (Table 3). The liver function pa-
rameters according to the different mutations in HFE are
given in Table 7.
Multivariate analysis revealed an independent positive
association of hepatitis C infection (P = 0.04) and HFE
mutations (P = 0.003) with ALAT. Furthermore, hepati-
tis C infection was independently associated with higher
ASAT (P < 0.001) and GGT levels (P = 0.01).
Liver disease and mortality rates
None of the patients with mutations in HFE suffered
from viral hepatitis. In contrast, hepatitis B or C infection
was present in 7 of 21 patients without mutations in HFE
(33%, one patient with hepatitis B and six patients with
hepatitis C).
One patient died because of liver failure. This patient
was homozygous for HFE C282Y. One patient presented
with liver cirrhosis. This patient showed wild-type HFE
alleles and suffered from a hepatitis C infection.
No case of alcoholic liver disease was documented
among study patients.
Five-year mortality rates were 24% in patients without
mutations in HFE, and 25% in patients with mutations
in HFE.
DISCUSSION
The prevalence of iron overload was 9.4% among 438
long-term renal transplant patients. Thirty-six percent of
cases with iron overload exhibited mutations in the HFE
gene whereas the TRF2 X250Y mutation was not identi-
fied. Over time, we observed a less pronounced decrease
of biochemical markers of iron overload in patients with
mutations as compared to individuals without mutations.
A multiple stepwise regression analysis revealed that the
presence of mutations in the HFE gene was significantly
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Table 3. Comparison of the change () of serum iron, serum ferritin,
transferring saturation (TSAT), alanine-aminotransferase (ALAT),
asparte-aminotransferase (ASAT), and gamma-glutamyl-transferase
(GGT) between 1995 and 2000 in patients with and without mutations
in HFE
Mean Mean
(mutation) (no mutation) P valuea
Iron −14.0 −45.6 0.07
Ferritin −342 −618 0.2
TSAT −6.62 −13.1 0.4
ALAT −1.17 −2.05 0.8
ASAT −2.33 +0.05 0.3
GGT −63.8 −3.95 0.1
at tests for independent samples.
associated with higher serum ALAT levels at 5 years of
follow-up.
Iron deficiency is present in 20.1% of long-term kidney
transplant recipients and is attributable to occult blood
losses, blood sampling, and low-meat dietary regimens
[6]. By contrast, the prevalence of iron overload has been
unknown. However, end-stage renal disease (ESRD) pa-
tients are at risk for iron overload as a consequence of red
blood cell transfusions [5, 9] and intravenous injection
of iron for correction of iron deficiency and renal ane-
mia [10]. Among our study population 56% of patients
were already maintained under renal replacement ther-
apy before introduction of erythropoietin treatment and
thus most of them had frequently received red blood cell
transfusions because of persistent anemia. Thus, transfu-
sional iron overload may explain iron overload in a large
proportion of our patients.
Following introduction of recombinant human ery-
thropoietin the prevalence of transfusional iron overload
among ESRD patients decreased rapidly [11, 12]. Al-
though erythropoietin is now widely used for correction
of renal anemia iron overload still represents a possible
complication because intravenous iron therapy is often
required to maintain adequate iron stores for successful
erythropoietin treatment [13, 14]. Among our 438 pa-
tients who had been transplanted almost 3 years ago 41
individuals still showed biochemical indices of iron over-
load although they had not received further iron sup-
plementation. Other causes that could have contributed
to the biochemical phenotype of iron overload in our
patients include systemic inflammation, malignant dis-
orders, and viral hepatitis. Among our renal transplants
17% showed evidence of a viral hepatitis, and 9% exhib-
ited signs of systemic inflammation as reflected by ele-
vated CRP concentrations in serum (3% of cases) and/or
high ferritin levels and a TSAT below 15% (6% of cases).
One patient (3%) suffered from lung cancer. Thus, in 29%
of our patients the presence of a viral hepatitis, systemic
inflammation or a malignancy could explain the bio-
chemical signs of iron overload. Furthermore, excessive
alcohol consumption can be associated with significantly
higher serum ferritin, iron, and TSAT [15]. However, in
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Table 4 Time course of iron parameters in patients with different mutations in HFE (median, range in parenthesis)
282YY 282CY/63HDa 282CY 63HD
(N = 1) (N = 2) (N = 2) (N = 7)
1995 2000 1995 2000 1995 2000 1995 2000
Serum iron lg/dL 128 182 132.5 (125; 140) 110.5 (81; 140) 103.5 (44; 163) 150.5 (92; 209) 115 (50; 142) 75.0 (51; 113)
Ferritin ng/mL 933 759 634 (138; 1130) 332 (267; 397) 1195 (70; 2320) 873 (125; 1620) 843 (118; 1640) 335 (40; 1450)
Transferrin saturation % 57.1 82.7 53.2 (42.8; 63.6) 46.9 (38.3; 55.5) 68.4 (54.2; 82.6) 49.3 (36.2; 62.3) 32.5 (17.0; 62.5) 26.7 (17; 43.5)
aOne C282Y/C282Y genotype, two patients C282Y/H63D genotype; two patients heterozygous for C282Y; seven patients heterozygous for H63D.
Table 5. Independent associations with transferrin saturation (TSAT)
in the year 2000 (follow-up of 5 years) in 33 renal transplant patients
with iron overload (by multiple stepwise regression analysisa)
b coefficient P value
Gamma-glutamyl-transferase 1995 0.407 0.01
Years since transplantation 0.388 0.04
Alanine aminotransferase 1995 0.605 0.006
Hepatitis C −0.468 0.01
Creatinine clearance 0.483 0.02
Age 0.422 0.01
ar2 0.65167990, P < 0.00016; selection cut-off: F >1, the variables follow the
order in which they entered in the equation. Asparate aminotranferase 1995,
saturation of transferrin 1995, serum creatinine 1995, prothrombin time 1995,
and serum ferritin 1995 were not significant.
none of our patients excessive alcohol consumption had
been documented.
At this point, it must be considered that on the basis of
increased serum ferritin concentrations it cannot be con-
cluded that our patients suffered from iron-related tis-
sue damage. We only have investigated the biochemical
phenotype that can be influenced by factors others than
those causing parenchymal damage and organ dysfunc-
tion. Whether or not the increased TSAT and hyperfer-
ritinemia indicate the presence of tissue/organ damage
and thus is harmful for patients remains to be clarified
(e.g., analysis of tissue iron concentrations). However,
since the presence of a systemic inflammation, and liver
disease could be excluded in about 70% of our patients
and because the patients were old enough to develop iron
overload disease (mean age of the study population was
54.4 years), the biochemical markers indeed could re-
flect the presence of tissue iron overload (and thus tis-
sue/organ damage) in a substantial number of patients.
Besides the before-mentioned causes genetic factors
may predispose to iron overload. In apparently healthy
individuals, heterozygosity, compound heterozygosity,
and homozygosity for HFE C282Y and HFE H63D are
associated with a significant higher TSAT in serum as
compared to individuals with wild-type alleles [16–19].
The HFE S65C mutation possibly also influences TSAT,
although this effect seems to be weaker as compared to
HFE C282Y and HFE H63D [20, 21].
In the present study we have investigated 12 different
iron loading mutations including theTRF2 Y250X that
has been shown to result in a clinical phenotype com-
parable with HFE C282Y homozygotes [3, 4, 22–24]. In
our study population only the HFE C282Y and the HFE
H63D mutation have been found whereas HFE V53M,
V59M, H63H, S65C, Q127H, E168Q, E168X, W169X,
Q283P, as well as the TRF2 Y250X mutation were not
identified. These data suggest that mutations other than
HFE C282Y and H63D are not necessarily associated
with iron overload in kidney transplant recipients.
During a time period of 5 years we observed a decrease
of mean iron levels, of mean ferritin levels, and of mean
TSAT among our renal transplant patients which is pos-
sibly attributable, at least in part, to the endogenous syn-
thesis of erythropoietin by the donor kidney ultimately
leading to mobilization of the iron stores for hemoglobin
synthesis. Interestingly, in patients showing mutations in
HFE this decrease was less pronounced as compared to
individuals without mutations suggesting that recovery
from secondary iron overload after renal transplantation
is influenced by the HFE C282Y and H63D mutations. In
our study all evaluated markers of iron status (i.e., serum
iron, serum ferritin, and TSAT) decreased not as much
as in patients with a mutation in HFE as compared to pa-
tients showing wild-type alleles. The greatest difference
was observed for serum iron levels. However, these dif-
ferences only showed borderline significance which might
have been due to a too short follow-up. Of note the pa-
tient homozygous for HFE C282Y developed even an
increase of serum iron and TSAT during follow-up sug-
gesting that homozygosity for HFE C282Y can aggravate
the time course of iron overload in renal transplant pa-
tients.
According to the Kidney/Disease Outcomes Quality
Initiative (K/DOQI) guidelines of the National Kidney
Foundation [25], the precise levels of TSAT or serum fer-
ritin above which patients with chronic kidney disease
will have iron overload is not known. In the present study
we have chosen a TSAT above 40% as suggested by the
American Hemochromatosis Society and/or a serum fer-
ritin concentration of more than 800 ng/mL as cut-off lev-
els because our study population represented stable renal
transplant patients. Using this threshold for iron overload
we identified heterozygosity, homozygosity, or compound
heterozygosity for HFE C282Y and HFE H63D in 36.3%
of cases. This proportion is comparable with the preva-
lence of 31.4% reported among unselected hemodialy-
sis patients from the same geographic era [26] as well as
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Table 6. Time course of liver enzymes and prothrombin time (median, range in parenthesis)
All patients (N = 41) DNA available (N = 33) Mutation (N = 12) Wild-type (N = 21)
Year 1995 2000 1995 2000 1995 2000 1995 2000
ASAT U/L 9 (5; 31) 10 (3; 35) 9 (6; 31) 10 (3; 35) 9.5 (7; 31) 9.5 (3; 17) 9 (6; 26) 10 (5; 35)
ALAT U/L 9 (3; 47) 9.5 (1; 24) 9 (3; 47) 9 (2; 24) 9 (6; 28) 10 (2; 22) 9 (3; 47) 9 (4; 24)
GGT U/L 17 (4; 922) 14 (5; 347) 17 (4; 922) 13 (5; 347) 22.5 (5; 922) 16 (6; 347) 17 (4; 72) 11 (5; 89)
PT% 110 (61; 150) 122 (44; 150) 110 (61; 150) 122.0 (44; 150) 110 (77; 150) 138.5 (70; 150) 109 (61; 150) 117 (44; 150)
Abbreviations are ASAT, aspartate-aminotransferase, ALAT, alanine-aminotransferase; GGT, gamma-glutamyl-transferase; PT, prothrombin time.
Table 7. Time course of liver enzymes in patients with different mutations in HFE (median, range in parenthesis)
282YY (N = 1) 282CY/63HDa (N = 2) 282CY (N = 2) 63 HD (N = 7)
1995 2000 1995 2000 1995 2000 1995 2000
ASAT U/L 31 13 8.5 (8; 9) 9 (9) 12 (9; 15) 9.5 (8; 11) 9 (7; 21) 10 (3; 17)
ALAT U/L 28 12 10 (6; 14) 9.5 (8; 11) 11.5 (6; 17) 8 (6; 10) 9 (6; 15) 10 (2; 22)
GGT U/L 922 347 66 (8; 124) 24.5 (7; 42) 15.5 (9; 22) 19.5 (12; 27) 24.5 (5; 115) 15 (6; 43)
Abbreviations are: ASAT, aspartate-aminotransferase, ALAT, alanine-aminotransferase; GGT, gamma-glutamyl-transferase.
aOne C282Y/C282Y genotype, two patients C282Y/H63D genotype; two patients heterozygous for C282Y; seven patients heterozygous for H63D.
individuals of the general population of America and Eu-
rope [27], suggesting no major role of HFE C282Y and
HFE H63D in the development of iron overload in renal
transplant patients. Nevertheless, the above-mentioned
threshold allowed identification of one individual ho-
mozygous for HFE C282Y and two subjects compound
heterozygous for HFE C282Y and HFE H63D suggesting
high detection sensitivity.
In our study we observed no changes of liver enzymes in
patients with iron overload without mutations in HFE. In
contrast, HFE mutations were independently associated
with ALAT levels. In this context, none of the patients
showing mutations in HFE suffered from viral hepatitis
or excessive alcohol consumption suggesting an effect of
mutations in HFE on liver function in our study cohort.
In this regard, an influence of the HFE C282Y mutation
on liver function tests (serum ASAT concentration) has
been observed among individuals homozygous for HFE
C282Y [28].
Limitations to our study comprise the small sample
size. However, all patients showing biochemical indices of
iron overload of a large population of 438 renal transplant
patients were included. Another limitation is that only
mutations in HFE and TRF2 have been analyzed. We did
not test for other genes/mutations such as HAMP [29–
31].
CONCLUSION
Our study demonstrates that almost 10% of renal trans-
plants show biochemical signs of iron overload even after
3 years of renal transplantation. During a further follow-
up of 5 years all serologic markers of iron overload de-
creased. This decrease was ameliorated by the presence
of the HFE C282Y and HFE H63D mutations. Moreover
mutations in HFE significantly influenced ALAT serum
concentrations. Thus our study suggests a role of HFE
C282Y and H63D in the course of iron overload and liver
function among renal transplant patients.
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